Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration

AIDS

Volumn 26, Issue 7, 2012, Pages 890-893

  Croteau, David ^a   Best, Brookie M ^a,c   Letendre, Scott ^a   Rossi, Steven S ^a   Ellis, Ronald J ^a   Clifford, David B ^d   Collier, Ann C ^e   Gelman, Benjamin B ^f   McArthur, Justin C ^g   McCutchan, John Allen ^a   Morgello, Susan ^h   Grant, Igor ^b  

^a RADY CHILDREN'S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; MARAVIROC;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MALE; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY; WILD TYPE;

ADULT; CHROMATOGRAPHY, REVERSE-PHASE; CROSS-SECTIONAL STUDIES; CYCLOHEXANES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MIDDLE AGED; RECEPTORS, CCR5; RNA, VIRAL; TANDEM MASS SPECTROMETRY; TRIAZOLES;

EID: 84859996096     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328351f627     Document Type: Article

References (12)

1. Letendre SL, van den Brande G, Hermes A, Woods SP, Durelle J, Marquie Beck J, et al. Lopinavir with ritonavir reduces the HIV RNA level in cerebrospinal fluid. Clin Infect Dis 2007; 54:1511-1517. (Pubitemid 351411885)
2. Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009; 23:1359-1366.
3. Letendre SL, McCutchan JA, Childers ME, Woods SP, Lazzaretto D, Heaton RK, et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol 2004; 56:416-423. (Pubitemid 39166561)
4. Smurzynski M, Wu K, Letendre S, Robertson K, Bosch RJ, Clifford DB, et al. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 2011; 25:357-365.
5. Albright AV, Shieh JT, Itoh T, Lee B, Pleasure D, O'Connor MJ, et al. Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates. J Virol 1999; 73:205-213. (Pubitemid 28565362)
6. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum antihuman immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49:4721-4732. (Pubitemid 41552605)
7. Walker DK, Abel S, Comby P, Muirhead GJ, Nedderman AN, Smith DA. Species differences in the disposition of the CCR5 antagonist, UK-427857, a new potential treatment of HIV. Drug Metab Dispos 2005; 33:587-595. (Pubitemid 40393203)
8. Haas DW, Johnson B, Nicotera J, Bailey VL, Harris VL, Bowles FB, et al. Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma. Antimicrob Agents Chemother 2003; 47:2131-2137. (Pubitemid 36753562)
9. Adam P, Sobek O, Taborsky L, Hildebrand T, Tutterova O, Zacek P. CSF and serum orosomucoid (alpha-1-acid glycoprotein) in patients with multiple sclerosis: a comparison among particular subgroups of MS patients. Clin Chim Acta 2003; 334:107-110. (Pubitemid 36836063)
10. Walker DK, Bowers SJ, Mitchell RJ, Potchoiba MJ, Schroeder CM, Small HF. Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency (HIV) sanctuary sites in the central nervous system (CNS) and gutassociated lymphoid tissue (GALT). Xenobiotica 2008; 38: 1330-1339.
11. Tiraboschi JM, Niubo J, Curto J, Podzamczer D. Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients. J Acquir Immune Defic Syndr 2010; 55:606-609.
12. Yilmaz A, Watson V, Else L, Gisslen M. Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients. AIDS 2009; 23:2537-2540.